Role of ¿1-pyrroline-5-carboxylate dehydrogenase supports mitochondrial metabolism and host-cell invasion of Trypanosoma cruzi

Proline is crucial for energizing critical events throughout the life cycle of Trypanosoma cruzi, the etiological agent of Chagas disease. The proline breakdown pathway consists of two oxidation steps, both of which produce reducing equivalents as follows: the conversion of proline to ¿1-pyrroline-5-carboxylate (P5C), and the subsequent conversion of P5C to glutamate. We have identified and characterized the ¿1-pyrroline-5-carboxy- late dehydrogenase from T. cruzi (TcP5CDH) and report here on how this enzyme contributes to a central metabolic pathway in this parasite. Size-exclusion chromatography, two-dimen- sional gel electrophoresis, and small angle x-ray scattering analysis of TcP5CDH revealed an oligomeric state composed of two subunits of six protomers. TcP5CDH was found to complement a yeast strain deficient in PUT2 activity, confirming the enzyme’s functional role; and the biochemical parameters (Km, kcat, and kcat/Km) of the recombinant TcP5CDH were determined, exhibiting values comparable with those from T. cruzi lysates. In addition, TcP5CDH exhibited mitochondrial staining during the main stages of the T. cruzi life cycle. mRNA and enzymatic activity levels indicated the up-regulation (6-fold change) of TcP5CDH during the infective stages of the parasite. The participation of P5C as an energy source was also demonstrated. Overall, we propose that this enzymatic step is crucial for the viability of both replicative and infective forms of T. cruzi

Chemotherapy Of Chagas' Disease: State Of The Art And Perspectives For The Development Of New Drugs [quimioterapia Da Doença De Chagas: Estado Da Arte E Perspectivas No Desenvolvimento De Novos Fármacos]

Neglected diseases are a major global cause of illness, long-term disability and death. Chagas' disease is a parasitic infection widely distributed throughout Latin America, with devastating consequences in terms of human morbidity and mortality. The existing drug therapy suffers from a combination of drawbacks including poor efficacy, resistance and serious side effects. In 2009, we celebrate the 100th anniversary of the discovery of Chagas' disease, facing the challenges of developing new, safe and effective drugs for the treatment of this disease. This brief review attempts to highlight the state of the art, limitations and perspectives of Chagas' disease drug development.32924442457Ketter, H., Marjanovic, S., (2004) Nature Rev. Drug Discov., 3, p. 171Nwaka, S., Ridley, R.G., (2003) Nature Rev. Drug Discov., 2, p. 919Engels, D., Savioli, L., (2006) Trends Parasitol., 22, p. 363Gelb, M.H., Hol, W.G., (2002) Science, 297, p. 343Hoare, C.A., (1972) The Trypanosomes of Mammals, p. 20. , Blackwell Scientific Publications: OxfordHoare, C.A., Wallace, F.G., (1966) Nature, 212, p. 1385Boainain, E., Rassi, A., Arq. Bras. Cardiol., 32, pp. 1979-2395Dias, J.C., (1993) Cad. Saúde Pub. Minist. Saúde, 9, p. 201. , Fundação Oswaldo Cruz, Escola Nacional de Saúde PúblicaMarin-Neto, J.A., Simões, M.V., Maciel, B.C., Uptodate in Cardiovascular Medicine, , A CD-Rom Textbook, Section: CardiomyopathiesRose, B.D., Podrid, P.J., Gersh, B.J., (1998) Orgs., 6, p. 6. , 1st ed. Wellesley: Ma, USARossi, M.A., (1991) Int. J. Cardiol., 30, p. 335Kalil, J., Cunha-Neto, E., (1996) Parasitol. Today, 12, p. 396Bellotti, G., Bocchi, E.A., De Moraes, A.V., Higuchi, M.L., Barbero-Marcial, M., Sosa, E., (1996) Am. Heart J., 131, p. 301Levin, M.J., (1996) Parasitol. Today, 12, p. 415Hayes, R., Schofield, C.J., (1990) Volví. Oficial Sanit. Panam., 108, p. 308(1991) World Health Organization Tech. Rep. Ser., 811, p. 1. , WHODias, J.C., (1995) Parasitol. Today, 3, p. 336Brener, Z., Andrade, Z., (1979) Trypanosoma cruzi e Doença de Chagas, p. 362. , Guanabara Koogan: Rio de JaneiroBrener, Z., (1968) Terapêutica Experimental da Doença de Chagas, p. 510. , Cançado, J. R. ed. Imprensa Oficial de Minas Gerais: Belo HorizonteCoura, J.R., Castro, S.L., (2002) Mem. Inst. Oswaldo Cruz, 97, p. 3De Castro, S.L., (1993) Acta Tropical, 53, p. 83Brener, Z., (1961) Rev. Inst. Med. Trop., 3, p. 43. , São PauloCançado, J.R., Marra, U.D., Brener, Z., (1964) Rev. Inst. Med. Trop., 6, p. 12. , São PauloPackchanian, A., (1952) J. Parasitol., 38, p. 30Packchanian, A., (1957) Antib. Chemother., 7, p. 13Rassi, A., Ferreira, H.O., (1971) Rev. Inst. Med. Trop., 5, p. 235. , São PauloCoura, J.R., Ferreira, L.F., Silva, J.R., (1962) O Hospital, 62, p. 957Ferreira, H.O., (1961) Rev. Inst. Med. Trop., 3, p. 287. , São PauloCoura, J.R., Castro, S.L., (2002) Mem. Inst., 97, p. 3. , Oswaldo CruzRubio, M., Donoso, F., (1969) Bol. Chil. Parasitol., 24, p. 43Schenone, H., Concha, L., Aranda, R., Rojas, A., Alfaro, E., Knierin, E., Rojo, M., (1975) Bol. Chil. Parasitol., 30, p. 91Schenone, H., Concha, L., Aranda, R., Rojas, A., Knierim, F., Rojo, M., (1972) Bol. Chil. Parasitol., 27, p. 11Maya, J.D., Bollo, S., Nuñez-Vergara, L.J., Squella, J.A., Repetto, Y., Morello, A., Périé, J., Chauvière, G., (2003) Biochem. Pharmacol., 65, p. 999Maya, J.D., Cassels, B.K., Iturriaga-Ásquez V, P., Ferreira, J., Faúdez, M., Galanti, N., Ferreira, A., Morello, A., (2007) Comp. Bio-chem. Physiol. A Mol. Integr. Physiol., 146, p. 601Moreno, S.N., Docampo, R., Mason, R.P., León, W., Stoppani, A.O., (1982) Archiv. Biochem Biophys., 218, p. 585Mason, R.P., Holtzman, J.L., (1975) Biochem. Biophys. Res. Commun., 67, p. 1267Temperton, N.J., Wilkinson, S.R., Meyer, D.J., Kelly, J.M., (1998) Mol. Biochem. Parasitol., 96, p. 167Docampo, R., Moreno, S.N., (1984) Rev. Infec. Diseases, 6, p. 223Docampo, R., Moreno, S.N., Stoppani, A.O., León, W., Cruz, F.S., Villalta, F., Muñiz, R.F., (1981) Biochem. Pharmacol., 30, p. 1947Díaz De Toranzo, E.G., Castro, J.A., Franke De Cazzulo, B.M., Cazzulo, J.J., (1988) Experientia, 44, p. 880Romanha, A.J., Alves, R.O., Murta, S.M., Silva, J.S., Ropert, C., Gazzinelli, R.T., (2002) J. Infec. Diseases, 186, p. 823Turrens, J.F., Watts Jr., B.P., Zhong, L., Docampo, R., (1996) Mol. Biochem. Parasitol., 82, p. 125Castro, J.A., Meca, M.M., Bartel, L.C., (2006) Hum. Exp. Toxicol., 25, p. 471Nwaka, S., Hudson, A., (2006) Nature Rev., 5, p. 941Kola, I., (2008) Mol. Therapy, 83, p. 227Duschak, V.G., Couto, A.S., (2007) Recent Pat. Anti-Infec Drug Discov., 2, p. 19McKerrow, J.H., Rosenthal, P.J., Swenerton, R., Doyle, P., (2008) Cur. Opin. Infc. Dis., 21, p. 668Andricopulo, A.D., Yunes, R.A., Nunes, R.J., Savi, A.O.S., Cruz, A.B., Cechinel, V., (1998) Quim. Nova, 21, p. 573Sealey-Cardona, M., Cammerer, S., Jones, S., Ruiz-Perez, L.M., Brun, R., Gilbert, I.H., Urbina, J.A., Gonzalez-Pacanowska, D., (2007) Antimicrob. Agents Chemother., 51, p. 2123Jr., W.F.A., Soares, M.B.P., (2009) Cur. Drug Targets, 10, p. 193Moreira, D.R.M., Leite, A.C.L., Dos Santos, R.R., Soares, M.B.P., (2009) Cur. Drug Targets, 10, p. 212Soeiro, M.N.C., Castro, S.L., (2009) Expert. Opinion, 13, p. 105Sajid, M., McKerrow, J.H., (2002) Mol. Biochem. Parasitol., 120, p. 1Brak, K., Doyle, P.S., McKerrow, J.H., Ellman, J.A., (2008) J. Am. Chem. Soc., 130, p. 6404Zanatta, N., Amaral, S.S., Dos Santos, J.M., De Mello, D.L., Fernandes, L.S., Bonacorso, H.G., Martins, M.A.P., Borchhardt, D.M., (2008) Biorg. Med. Chem., 16, p. 10236Fricker, S.P., Mosi, R.M., Cameron, B.R., Baird, I., Zhu, Y., Anastassov, V., Cox, J., McKerrow, J.H., (2008) J. Inorg. Biochem., 102, p. 1839Ascenzi, P., Salvati, L., Bolognesi, M., Colasanti, M., Polticelli, F., Venturini, G., (2001) Curr. Prot. Pept. Sci., 2, p. 137Silva, J.J.N., Osakabe, A.L., Pavanelli, W.R., Silva, J.S., Franco, D.W., (2007) Br. J. Pharmacol., 152, p. 112Doyle, P., Zhou, Y.M., Engel, J.C., McKerrow, J.H., (2007) Antimicrob. Agents Chemother., 51, p. 3932Apt, W., Aguilera, X., Arribada, A., Perez, C., Miranda, C., Sanchez, G., Zulantay, I., Júri, D., (1998) Am. J. Trop. Med. Hyg., 59, p. 133Hucke, O., Gelb, M.H., Verlinde, C.L., Buckner, F.S., (2005) J. Med. Chem., 48, p. 5415Kraus, J.M., Verlinde, C.L., Karimi, M., Lepesheva, G.I., Gelb, M.H., Buckner, F.S., (2009) J. Med. Chem., 52, p. 1639Verline, C.L.M.J., Hannaert, V., Blonski, C., Willson, M., Périé, J.J., Fathergill-Gilmore, L.A., Opperdoes, F.R., Michels, P.A.M., (2001) Antimicrob. Anticancer Chemother., 4, p. 1Souza, D.H.F., Garratt, R.C., Araújo, A.P.U., Guimarães, B.G., Jesus, W.D.P., Michels, P.A.M., Hannaert, V., Oliva, G., (1998) FEBS Lett., 424, p. 131Urbina, J.A., Crespo, A., (1984) Mol. Biochem. Parasitol., 11, p. 225Freitas, R.F., Prokopczyk, I.M., Zottis, A., Oliva, G., Andricopulo, A.D., Trevisan, M.T.S., Villegas, W., Montanari, C.A., (2009) Bioorg. Med. Chem., 17, p. 2476Pereira, J.M., Severino, R.P., Vieira, P.C., Fernandes, J.B., Silva, M.F.G.F., Zottis, A., Andricopulo, A.D., Correa, A.G., (2008) Bioorg. Med. Chem., 16, p. 8889Mohr, S., Stamler, J.S., Brüne, B., (1994) FEBS Lett., 348, p. 223Lopez, B.E., Wink, D.A., Fukuto, J.M., (2007) Arch. Biochem. Biophys., 465, p. 430Silva, J.J.N., Guedes, P.M.M., Zottis, A., Balliano, T.L., Da Silva, F.O.N., Lopes, L.G.F., Ellena, J., Franco, D.W., (2009) Br. J. Pharmacol., , in pressWilkinson, S.R., Kelly, J.M., (2003) Molecular Mechanisms in the Pathogenesis of Chagas' Disease, p. 56. , Kelly, J. M. ed. Landes Bioscience: LondonSilva, J.J.N., Pavanelli, W.R., Gutierrez, F.R.S., Lima, F.C.A., Silva, A.B.F., Silva, J.S., Franco, D.W., (2008) J. Med. Chem., 51, p. 4104Gutteridge, J.M., Halliwell, B., (2000) Ann. New York Acad. Sci., 899, p. 136Lopez, J.A., Carvalho, T.U., De Souza, W., Flohe, L., Guerrero, S.A., Montemartini, M., Kalisz, H.M., Colli, W., (2000) Free Radic. Biol. Med., 28, p. 767Frasch, A.C.C., Leguizamon, M.S., Campetella, O., Russomando, G., (1994) J. Infect. Dis., 170, p. 1570Tse-Dinh, Y.C., (2007) Infect. Disord. Drug Targets, 7, p. 3Guido, R.V.C., Oliva, G., Andricopulo, A.D., (2008) Cur. Med. Chem., 15, p. 37Andricopulo, A.D., Montanari, C.A., (2005) Mini-Rev. Med. Chem., 5, p. 585Andricopulo, A.D., Akoachere, M.B., Krogh, R., Nickel, C., Mcleish, M.J., Kenyon, G.L., Arscott, L.D., Becker, K., (2006) Bioorg. Med. Chem. Lett., 16, p. 2283Chung, M.C., Guido, R.V.C., Martinelli, T.F., Goncalves, M.F., Polli, M.C., Botelho, K.C.A., Varanda, E.A., Ferreira, E.I., (2003) Bioorg. Med. Chem., 11, p. 4779Cerecetto, H., Di Maio, R., González, M., Risso, M., Saenz, P., Seoane, G., Denicola, A., Olea-Azar, C., (1999) J. Med. Chem., 42, p. 1941Aguirre, G., Cerecetto, H., Di Maio, R., González, M., Porcal, W., Seoane, G., Denicola, A., Monge-Vega, A., (2002) Arch. Pharm., 335, p. 15Olea-Azar, C., Rigol, C., Opazo, L., Morello, A., Maya, J.D., Repetto, Y., Aguirre, G., Porcal, W., (2003) J. Chil. Chem. Soc., 48, p. 77Olea-Azar, C., Rigol, C., Mendizábal, F., Briones, R., Cerecetto, H., Di Maio, R., González, M., Risso, M., (2003) Spectrochim. Acta Part A, 59, p. 69Olea-Azar, C., Rigol, C., Mendizábal, F., Cerecetto, H., Di Maio, R., González, M., Porcal, W., Maya, J.D., (2005) Lett. Drug Des. Discov., 2, p. 294Aguirre, G., Boiani, L., Boiani, M., Cerecetto, H., Di Maio, R., González, M., Porcal, W., Barreiro, E.J., (2005) Bioorg. Med. Chem., 13, p. 6336Aguirre, G., Boiani, L., Cerecetto, H., Di Maio, R., González, M., Porcal, W., Thomson, L., Moller, M., (2005) Bioorg. Med. Chem., 13, p. 6324Aguirre, G., Boiani, M., Cerecetto, H., Gerpe, A., González, M., Fernández, S., Denicola, A., Escario, J.A., (2004) Arch. Pharm., 337, p. 259Boiani, M., González, M., (2005) Mini-Rev. Med. Chem., 5, p. 235Fielden, R., Meth-Cohn, O., Price, D., Suschitzky, H., (1973) J. Chem. Soc., Perkin Trans., 1, p. 696Baliani, A., Bueno, G.J., Stewart, M.L., Yardley, V., Brun, R., Barrett, M.P., Gilbert, I.H., (2005) J. Med. Chem., 48, p. 5570Carter, N.S., Fairlamb, A.H., (1993) Nature, 361, p. 173Stewart, M.L., Bueno, G.J., Baliani, A., Klenke, B., Brun, R., Brock, J.M., Gilbert, I.H., Barrett, M.P., (2004) Antimicrob. Agents Chemother., 48, p. 1733Tye, C.-K., Kasinathan, G., Barrett, M.P., Brun, R., Doyle, V.E., Fairlamb, A.H., Weaver, R., Gilbert, I.H., (1998) Bioorg. Med. Chem., 8, p. 811Barrett, M.P., Fairlamb, A.H., (1999) Parasitol. Today, 15, p. 136Sanchez-Delgado, R.A., Anzellotti, A., (2004) Mini.-Rev. Med. Chem., 4, p. 23Otero, L., Vieites, M., Bioani, L., Denicola, A., Rigol, C., Opazo, L., Olea-Azar, C., Cerecetto, H., (2006) J. Med. Chem., 49, p. 3322Sanchez-Delgado, R.A., Navarro, M., Lazardi, K., Atencio, R., Capparelli, M., Vargas, F., Urbina, J.A., Mais, D., (1998) Inorg. Chim. Acta, 276, p. 528Buckner, F.S., Verlinde, C.L.M.J., La Flamme, A.C., Van Voorhis, W.C., (1996) Antimicrob. Agents Chemother., 40, p. 2592Bruce, R.D., (1985) Fund. Appl. Toxicol., 5, p. 151Brener, Z., (1962) Rev. Inst. Med. Trop., 4, p. 389http://apps.who.int/tdr/svc/research/lead-discovery-drugs, acessada em Maio 2009http://apps.who.int/tdr/svc/research/lead-discovery-drugs/ partnerships-networks, acessada em Maio 2009Chirac, P., Torreele, R., (2006) Lancet, 12, p. 1560http://www.dndi.org, acessada em Maio 2009http://www.dndi.org.br/Portugues/sobre_dndi.aspx, acessada em Maio 200

Aurapten, a coumarin with growth inhibition against Leishmania major promastigotes

Several natural compounds have been identified for the treatment of leishmaniasis. Among them are some alkaloids, chalcones, lactones, tetralones, and saponins. The new compound reported here, 7-geranyloxycoumarin, called aurapten, belongs to the chemical class of the coumarins and has a molecular weight of 298.37. The compund was extracted from the Rutaceae species Esenbeckia febrifuga and was purified from a hexane extract starting from 407.7 g of dried leaves and followed by four silica gel chromatographic fractionation steps using different solvents as the mobile phase. The resulting compound (47 mg) of shows significant growth inhibition with an LD50 of 30 µM against the tropical parasite Leishmania major, which causes severe clinical manifestations in humans and is endemic in the tropical and subtropical regions. In the present study, we investigated the atomic structure of aurapten in order to determine the existence of common structural motifs that might be related to other coumarins and potentially to other identified inhibitors of Leishmania growth and viability. This compound has a comparable inhibitory activity of other isolated molecules. The aurapten is a planar molecule constituted of an aromatic system with electron delocalization. A hydrophobic side chain consisting of ten carbon atoms with two double bonds and negative density has been identified and may be relevant for further compound synthesis